Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

First Annual Michael SanInocencio Lennox-Gastaut Syndrome Research Award Presented at Annual Meeting of the Child Neurology



   First Annual Michael SanInocencio Lennox-Gastaut Syndrome Research Award
          Presented at Annual Meeting of the Child Neurology Society

Award supports vital research to understand rare and severe form of epilepsy

PR Newswire

WOODCLIFF LAKE, N.J., Nov. 1, 2013

WOODCLIFF LAKE, N.J., Nov. 1, 2013 /PRNewswire/ -- The Child Neurology
Foundation (CNF) and Eisai Inc. today announced that the first annual Michael
SanInocencio Lennox-Gastaut Syndrome (LGS) Research Award was presented to
Maura Madou, MD, Child Neurology Fellow at University of California – San
Francisco, Benioff Children's Hospital, to facilitate her research on LGS. Dr.
Madou will receive a $30,000 grant to help support the first-ever genome-wide
study of the genetics of LGS, with the aim of identifying new targeted
therapies to treat the disease. The award is funded through a sponsorship from
Eisai Inc.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)

"We are proud to support continued research into LGS, a very severe form of
epilepsy, with the hope that one day it may improve the lives of people who
suffer from this devastating syndrome," said Lynn Kramer, MD, President of the
Neuroscience and General Medicine Product Creation Unit and Chief Clinical
Officer of Eisai Product Creation Systems, Eisai's research and development
organization.

LGS accounts for up to 4% of all childhood epilepsy cases and is characterized
by multiple seizure types and impairment of cognitive function. Dr. Madou was
selected to receive the award based on her proposal to expand upon the ongoing
Epilepsy Phenome Genome Project (EPGP), an international study devoted to
improving the medical community's understanding of epilepsy.

"We are very pleased to present the Michael SanInocencio LGS Research Award to
Dr. Madou, as she has already identified causative gene mutations in patients
with LGS," said child neurologist Donald Shields, MD, President of CNF. "We're
hopeful that the commitment by CNF, supported by Eisai, to present this award
annually will encourage other researchers to study the syndrome and its
treatment."

Madou was formally presented with the award on November 1 during the morning
session of the 2013 Child Neurology Society (CNS) annual meeting in Austin,
TX. She also was recognized at the CNF's donor luncheon on October 31, where
Christina SanInocencio, President of the LGS Foundation and sister of Michael
SanInocencio, acknowledged Madou's contributions to the field and spoke about
the importance of scientific research in furthering the understanding of LGS.

"I am thankful to Eisai and the Child Neurology Foundation for this award, and
for recognizing the dire need for expanded research into this condition,"
stated Dr. Madou. "By deepening our understanding of the genetic causes of
LGS, we hope to improve medical therapies for seizure control."

About the Research

The Michael SanInocencio LGS Award will fund an expansion of ongoing research
from the Epilepsy Phenome Genome Project (EPGP), an international epilepsy
study funded by the National Institutes of Neurological Disorders and Stroke.
As part of a broader study of epilepsy patients, EPGP researchers collected
DNA samples from more than 150 LGS patients and their families and conducted
whole exome gene sequencing to better understand the unique genetic
characteristics associated with this form of epilepsy. The award funds will
focus on expanding the LGS patient population and continuing to study in
genetic detail the DNA samples provided in an effort to identify new candidate
genes for LGS-specific therapeutic targets. The expanded research will also
include a review of all LGS patients currently enrolled in the EPGP as well as
new recruits to compare the newly identified genetic targets with real-life
clinical patient outcomes.

Child Neurology Foundation

Founded in October 2000, the Child Neurology Foundation's mission is to
advocate for children and adolescents with neurologic and developmental
disorders; fund neurologic research of young investigators; promote awareness
of career opportunities in child neurology; provide public, professional, and
patient education programs; and support the activities and mission of the
Child Neurology Society.

Eisai Inc.

At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., we have a passionate commitment to patient care that is the driving
force behind our efforts to help address unmet medical needs. We are a fully
integrated pharmaceutical business with discovery, clinical, manufacturing and
marketing capabilities. Our key areas of commercial focus include oncology and
specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To
learn more about Eisai Inc., please visit us at www.eisai.com/US. 

Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based
programs.

Media Inquiries
Laurie Landau
Eisai Inc.
201-746-2510

SOURCE Eisai Inc.

Website: http://www.eisai.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement